Page 1

West Exhibit 99.1 West Announces Third - Quarter 2021 Results and Declares Fourth - Quarter 2021 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton , PA , October 28 , 2021 - West Pharmaceutical Services , Inc. ( NYSE : WST ) today announced its financial results for the third - quarter 2021 and updated full - year 2021 financial guidance . Third - Quarter 2021 Summary ( comparisons to prior - year period ) • • Net sales of $ 706.5 million grew 28.9 % ; organic sales growth was 27.9 % . Reported - diluted EPS of $ 2.31 increased 112 % . • • Adjusted - diluted EPS of $ 2.06 increased 79 % . Company is raising full - year 2021 net sales guidance to a new range of $ 2.800 billion to $ 2.810 billion , compared to a prior range of $ 2.760 billion to $ 2.785 billion . Company is raising full - year 2021 adjusted - diluted EPS guidance to a new range of $ 8.40 to $ 8.50 , compared to a prior range of $ 8.05 to $ 8.20 . ⚫ The Company also announced that its Board of Directors has approved a fourth - quarter 2021 dividend of $ 0.18 per share , a 5.9 % increase over the $ 0.17 per share paid in each of the four preceding quarters . This is the twenty - ninth consecutive annual increase in the Company's dividend . The dividend will be paid on November 17 , 2021 , to shareholders of record as of November 10 , 2021 . " Adjusted - diluted EPS " and " organic sales growth " are Non - U.S . GAAP measurements . See discussion under the heading " Non - U.S . GAAP Financial Measures " in this release . " We had robust growth in all three of our Proprietary Products market units , led by the sales of components in our High - Value Product ( HVP ) portfolio , " said Eric M. Green , President and Chief Executive Officer . " This quarter's strong performance came from both our base business , especially in the Biologics market unit , and COVID - 19 related sales . Demand continues to grow for our premium offerings , such as NovaPure and FluroTec components , and , as a result , we are again increasing our planned capital expenditures , commencing next year , to expand HVP capacity at existing sites . " Proprietary Products Segment Net sales grew by 36.9 % to $ 577.0 million . Organic sales growth was 35.7 % , with currency translation increasing sales growth by 120 basis points . HVP sales represented over 70 % of segment sales and generated double - digit organic sales growth , led by customer demand for Westar® , FluroTec® and NovaPure® components and Daikyo Crystal Zenith® containers . All three market units - Biologics , Generics and Pharma - had strong double - digit organic sales growth .